PI
ADAP

Putnam Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Putnam Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-447,181
Closed -$3.15M – 1246
2016
Q3 		$3.15M Buy
447,181
+395,700
+769% +$3.02M 0.01% 713
2016
Q2 		$420K Hold
51,481
– – ﹤0.01% 1217
2016
Q1 		$419K Hold
51,481
– – ﹤0.01% 1276
2015
Q4 		$621K Hold
51,481
– – ﹤0.01% 1266
2015
Q3 		$616K Hold
51,481
– – ﹤0.01% 1282
2015
Q2 		$944K Buy
+51,481
New +$884K ﹤0.01% 1228

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Putnam Investments's ADAP Position: Q4 2016 in Review

Putnam Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2016, closing a stake of 447,181 shares — an estimated $3.15M sold.

Putnam Investments first reported a position in ADAP in Q2 2015 and held it in 6 quarters. The position peaked at $3.15M in Q3 2016. 40 funds tracked by Wall St. Rank hold ADAP as of Q4 2016.

  • Putnam Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Putnam Investments sold 447,181 Adaptimmune Therapeutics shares in Q4 2016, an estimated $3.15M.
  • Putnam Investments first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 6 quarters.
  • Putnam Investments's Adaptimmune Therapeutics position peaked at $3.15M in Q3 2016.
  • 40 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2016.

Based on Putnam Investments's 13F filing for Q4 2016, filed 14 Feb 2017.